Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease

J. Mestecky, BA. Julian, M. Raska

. 2023 ; 14 (-) : 1085922. [pub] 20230207

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004227

IgA nephropathy (IgAN) is an autoimmune disease in which poorly galactosylated IgA1 is the antigen recognized by naturally occurring anti-glycan antibodies, leading to formation of nephritogenic circulating immune complexes. Incidence of IgAN displays geographical and racial disparity: common in Europe, North America, Australia, and east Asia, uncommon in African Americans, many Asian and South American countries, Australian Aborigines, and rare in central Africa. In analyses of sera and cells from White IgAN patients, healthy controls, and African Americans, IgAN patients exhibited substantial enrichment for IgA-expressing B cells infected with Epstein-Barr virus (EBV), leading to enhanced production of poorly galactosylated IgA1. Disparities in incidence of IgAN may reflect a previously disregarded difference in the maturation of the IgA system as related to the timing of EBV infection. Compared with populations with higher incidences of IgAN, African Americans, African Blacks, and Australian Aborigines are more frequently infected with EBV during the first 1-2 years of life at the time of naturally occurring IgA deficiency when IgA cells are less numerous than in late childhood or adolescence. Therefore, in very young children EBV enters "non-IgA" cells. Ensuing immune responses prevent infection of IgA B cells during later exposure to EBV at older ages. Our data implicate EBV-infected cells as the source of poorly galactosylated IgA1 in circulating immune complexes and glomerular deposits in patients with IgAN. Thus, temporal differences in EBV primo-infection as related to naturally delayed maturation of the IgA system may contribute to geographic and racial variations in incidence of IgAN.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004227
003      
CZ-PrNML
005      
20230425141223.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2023.1085922 $2 doi
035    __
$a (PubMed)36865536
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mestecky, Jiri $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States $u Laboratory of Cellular and Molecular Immunology Institute of Microbiology, Czech Academy of Sciences, Prague, Czechia $u Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
245    10
$a IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease / $c J. Mestecky, BA. Julian, M. Raska
520    9_
$a IgA nephropathy (IgAN) is an autoimmune disease in which poorly galactosylated IgA1 is the antigen recognized by naturally occurring anti-glycan antibodies, leading to formation of nephritogenic circulating immune complexes. Incidence of IgAN displays geographical and racial disparity: common in Europe, North America, Australia, and east Asia, uncommon in African Americans, many Asian and South American countries, Australian Aborigines, and rare in central Africa. In analyses of sera and cells from White IgAN patients, healthy controls, and African Americans, IgAN patients exhibited substantial enrichment for IgA-expressing B cells infected with Epstein-Barr virus (EBV), leading to enhanced production of poorly galactosylated IgA1. Disparities in incidence of IgAN may reflect a previously disregarded difference in the maturation of the IgA system as related to the timing of EBV infection. Compared with populations with higher incidences of IgAN, African Americans, African Blacks, and Australian Aborigines are more frequently infected with EBV during the first 1-2 years of life at the time of naturally occurring IgA deficiency when IgA cells are less numerous than in late childhood or adolescence. Therefore, in very young children EBV enters "non-IgA" cells. Ensuing immune responses prevent infection of IgA B cells during later exposure to EBV at older ages. Our data implicate EBV-infected cells as the source of poorly galactosylated IgA1 in circulating immune complexes and glomerular deposits in patients with IgAN. Thus, temporal differences in EBV primo-infection as related to naturally delayed maturation of the IgA system may contribute to geographic and racial variations in incidence of IgAN.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a imunokomplex $7 D000936
650    12
$a infekce virem Epsteina-Barrové $x epidemiologie $x etnologie $7 D020031
650    12
$a IgA nefropatie $x epidemiologie $x etnologie $7 D005922
650    _2
$a virus Epsteinův-Barrové $7 D004854
650    _2
$a imunoglobulin A $7 D007070
650    _2
$a černoši $7 D044383
650    _2
$a kojenec $7 D007223
651    _2
$a Austrálie $7 D001315
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Julian, Bruce A $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States $u Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
700    1_
$a Raska, Milan $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 14, č. - (2023), s. 1085922
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36865536 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141220 $b ABA008
999    __
$a ok $b bmc $g 1924725 $s 1190436
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1085922 $e 20230207 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace